825 INDUSTRIAL ROAD, SAN CARLOS, CA
Corporate Overview June 2026
Amtagvi® (lifileucel) Granted Approval for the Treatment of Advanced Melanoma in Australia
Highlights Positive First Quarter 2026 Results, Business Achievements and Corporate Updates
Annual Report to Security Holders
Director Retirement - Wendy Yarno Not Standing for Re-Election
Highlights Strong Fourth Quarter and Full Year 2025 Results, Business Achievements and Corporate Updates
Corporate Overview January 2026
Highlights Business Achievements, Pipeline Milestones, and Third Quarter 2025 Results
Q1
FY 2024
Q3
Q2
FY 2023
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Submission Upload
Correspondence